On Tuesday, Merck & Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib). The trial met one ...
Richard Sherman and his fellow Prime Video sports analysts lost it at Red Panda's routine. / via NBA on Prime Thursday night was a special one for Amazon's ever expanding presence in the world of ...
A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...
A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer. Adding the drug enzalutamide to standard hormone therapy reduced the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results